7-(4-chloro-benzyl)-5,9-dihydroxy-pyrrolo[3,4-g]quinoxaline-6,8-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 7-(4-chloro-benzyl)-5,9-dihydroxy-pyrrolo[3,4-g]quinoxaline-6,8-dione
• 英文别名: 7-[(4-chlorophenyl)methyl]-5,9-dihydroxypyrrolo[3,4-g]quinoxaline-6,8-dione
• 化学式: C₁₇H₁₀ClN₃O₄
• 分子量: 355.737
• InChiKey: AWTLBSRRXAVXSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.49
• 重原子数：
  25.0
• 可旋转键数：
  2.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  103.62
• 氢给体数：
  2.0
• 氢受体数：
  6.0

反应信息

• 作为产物：
  描述：

  1-[(4-氯苯基)甲基]吡咯烷-2,5-二酮 、 吡嗪-2,3-二羧酸 二甲酯 在 甲醇 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 以48%的产率得到7-(4-chloro-benzyl)-5,9-dihydroxy-pyrrolo[3,4-g]quinoxaline-6,8-dione
  参考文献：
  名称：

  Design and Optimization of Tricyclic Phtalimide Analogues as Novel Inhibitors of HIV-1 Integrase

  摘要：

  Human immunodeficiency virus type-1 integrase is an essential enzyme for effective viral replication and hence a valid target for the design of inhibitors. We report here on the design and synthesis of a novel series of phthalimide analogues as integrase inhibitors. The short synthetic pathway enabled us to synthesize a series of analogues with a defined structure diversity. The presence of a single carbonyl-hydroxy-aromatic nitrogen motif was shown to be essential for the enzymatic activity and this was confirmed by molecular docking studies. The enzymatically most active compound from this series is 743,4-dichlorobenzyl)-5,9dihydroxypyrrolo[3,4-g]quinoxaline-6,8-dione (151) with an IC50 value of 112 nM on the HIV-1 integrase enzyme, while ((7-(4-chlorobenzyl)-5,9-dihydroxy-pyrrolo[3,4-g]quinoxaline-6,8-dione (15k)) showed an EC50 of 270 nM against HIV-1 in a cell-based assay.

  DOI：

  10.1021/jm049559q

文献信息

• Hiv integrase inhibitors
  申请人：Verschueren Wim Gaston

  公开号：US20060211724A1

  公开（公告）日：2006-09-21

  The present invention concerns the compounds having the formula (1), N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof wherein (a) or (b); A, together with the two carbons of the phenyl ring to which it is attached forms a monocyclic aryl or a monocyclic Het 2 ; R 1 is hydrogen, halo, nitro, cyano, sultam, sultim, C 3-7 cycloalkyl, C(═O)—R 5 , S(═O) y —R 6 , OR 7 , NR 8 R 9 , C(═NR 8 )—R 5 , optionally polysubstituted C 1-6 alkyl, optionally polysubstituted C 2-6 alkenyl or optionally polysubstituted C 2-6 alkynyl; R 2 is hydrogen, C 3-7 cycloalkyl, aryl, Het 1 , Het 2 , C(═O)—R 5 , S(═) y —R 6 OR 7 , NR 8 R 9 , C═NR 8 )—R 5 , or optionally polysubstituted C 1-6 alkyl, optionally polysubstituted C 2-6 alkenyl or optionally polysubstituted C 2-6 alkynyl. It further relates to their use as HIV integrase inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with other anti-retroviral agents, and to their use in assays as reference compounds or as reagents.

  本发明涉及具有式（1）的化合物，N-氧化物，盐，立体异构体，外消旋混合物，前药，酯和其代谢物，其中（a）或（b）; A与其附着的苯环的两个碳形成单环芳基或单环Het2; R1是氢，卤素，硝基，氰基，磺酰胺，磺酰亚胺，C3-7环烷基，C（═O）-R5，S（═O）y-R6，OR7，NR8R9，C（═NR8）-R5，可选地多取代的C1-6烷基，可选地多取代的C2-6烯基或可选地多取代的C2-6炔基; R2是氢，C3-7环烷基，芳基，Het1，Het2，C（═O）-R5，S（═）y-R6OR7，NR8R9，C═NR8）-R5，或可选地多取代的C1-6烷基，可选地多取代的C2-6烯基或可选地多取代的C2-6炔基。它进一步涉及它们作为HIV整合酶抑制剂的用途，它们的制备过程以及包含它们的制药组合物和诊断试剂盒。它还涉及它们与其他抗逆转录病毒药物的组合，以及它们作为参考化合物或试剂在测定中的使用。
• HIV INTEGRASE INHIBITORS
  申请人：Tibotec Pharmaceuticals Ltd.

  公开号：EP1625130A2

  公开（公告）日：2006-02-15
• [EN] HIV INTEGRASE INHIBITORS<br/>[FR] INHIBITEURS D'INTEGRASE VIH
  申请人：TIBOTEC PHARM LTD

  公开号：WO2004096807A2

  公开（公告）日：2004-11-11

  The present invention concerns the compounds having the formula (I), N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof wherein (a) or (b); A, together with the two carbons of the phenyl ring to which it is attached forms a monocyclic aryl or a monocyclic Het2 ; R1 is hydrogen, halo, nitro, cyano, sultam, sulltim, C3-7cycloalkyl, C(=O)-R5, S(=O)y-R6, OR 7, NR8R9, C(=NR8)-R5, optionally polysubstituted C1-6alkyl, optionally polysubstituted C2-6alkenyl or optionally polysubstituted C2-6alkynyl; R 2 is hydrogen, C3-7cycloalkyl, aryl, Het1, Het2, C(=O)-R5, S(=O)Y-R6 OR7, NR8R9, C=NR8)-R5, or optionally polysubstituted C1-6alkyl, optionally polysubstituted C2-6alkenyl or optionally polysubstituted C2-6alkynyl. It further relates to their use as HIV integrase inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with other anti-retroviral agents, and to their use in assays as reference compounds or as reagents.
• Design and Optimization of Tricyclic Phtalimide Analogues as Novel Inhibitors of HIV-1 Integrase
  作者：Wim G. Verschueren、Inge Dierynck、Katie I. E. Amssoms、Lili Hu、Paul M. J. G. Boonants、Geert M. E. Pille、Frits F. D. Daeyaert、Kurt Hertogs、Dominique L. N. G. Surleraux、Piet B. T. P. Wigerinck

  DOI：10.1021/jm049559q

  日期：2005.3.1

  Human immunodeficiency virus type-1 integrase is an essential enzyme for effective viral replication and hence a valid target for the design of inhibitors. We report here on the design and synthesis of a novel series of phthalimide analogues as integrase inhibitors. The short synthetic pathway enabled us to synthesize a series of analogues with a defined structure diversity. The presence of a single carbonyl-hydroxy-aromatic nitrogen motif was shown to be essential for the enzymatic activity and this was confirmed by molecular docking studies. The enzymatically most active compound from this series is 743,4-dichlorobenzyl)-5,9dihydroxypyrrolo[3,4-g]quinoxaline-6,8-dione (151) with an IC50 value of 112 nM on the HIV-1 integrase enzyme, while ((7-(4-chlorobenzyl)-5,9-dihydroxy-pyrrolo[3,4-g]quinoxaline-6,8-dione (15k)) showed an EC50 of 270 nM against HIV-1 in a cell-based assay.